Mark Yen
Impact in
- Urology top 10%
- Urinary Bladder and Prostate Research
-
- Parkinson's Disease Mechanisms and Treatments
Papers in
- Genetics 4
- Inflammatory Bowel Disease 4
- Co-authors
- Michael N. Hartnett (1 shared paper)M C Champion (1 shared paper)Salim Mujais (2 shared papers)Donna Kowalski (2 shared papers)James J. Keirns (2 shared papers)Larry Ereshefsky (5 shared papers)Marloes Schaddelee (1 shared paper)Selina Moy (1 shared paper)
- Journals
- Alzheimer s & Dementia (3 papers)Gastroenterology (3 papers)Clinical Pharmacology & Therapeutics (2 papers)Biomarkers in Medicine (1 paper)Talanta (1 paper)
- Partner nations
- United StatesUnited KingdomCanada
In The Last Decade
Mark Yen
17 papers receiving 435 citations
Peers
Comparison fields: 5 of 86
- Urology 43
- Neurology 41
- Gastroenterology 27
- Infectious Diseases 89
- Neurology 61
Countries citing papers authored by Mark Yen
This map shows the geographic impact of Mark Yen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Yen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Yen more than expected).
Fields of papers citing papers by Mark Yen
This network shows the impact of papers produced by Mark Yen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Yen. The network helps show where Mark Yen may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark Yen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2012 | 112 | |
| 2 | 2017 | 69 | |
| 3 | Domperidone, a new dopamine antagonist. | 1986 | 68 |
| 4 | 2017 | 59 | |
| 5 | 2008 | 47 | |
| 6 | 2012 | 46 | |
| 7 | 2015 | 15 | |
| 8 | 2015 | 9 | |
| 9 | 2009 | 6 | |
| 10 | 2010 | 6 | |
| 11 | 2009 | 5 | |
| 12 | 2025 | 1 | |
| 13 | 2024 | 1 | |
| 14 | 2024 | 1 | |
| 15 | 2013 | 1 | |
| 16 | 1982 | 1 | |
| 17 | 2012 | 1 | |
| 18 | 2025 | 0 |
About Mark Yen
Mark Yen is a scholar working on Molecular Biology, Genetics, Pharmacology, Physiology and Immunology, having authored 18 papers that have together received 448 indexed citations. Recurring topics across this work include Inflammatory Bowel Disease (4 papers), Alzheimer's disease research and treatments (3 papers), Biosimilars and Bioanalytical Methods (3 papers), Computational Drug Discovery Methods (2 papers), Parkinson's Disease Mechanisms and Treatments (2 papers), Statistical Methods in Clinical Trials (2 papers), Cardiac electrophysiology and arrhythmias (2 papers) and Cholinesterase and Neurodegenerative Diseases (2 papers). The work is most often cited by research in Urology (43 citations), Neurology (41 citations), Gastroenterology (27 citations), Infectious Diseases (89 citations) and Neurology (61 citations). Mark Yen has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Michael N. Hartnett, M C Champion, Salim Mujais, Donna Kowalski, James J. Keirns, Larry Ereshefsky, Marloes Schaddelee, Selina Moy, E. Marcel van Gelderen and Marek Malík. Their work appears in journals such as Alzheimer s & Dementia, Gastroenterology, Clinical Pharmacology & Therapeutics, Biomarkers in Medicine and Talanta.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.